Skip to main content
S&P 5007,704.42+1.79%DOW53,294.00+2.91%NASDAQ25,872.07+1.97%BTC$80,555.00+3.65%ETH$2,432.98+5.91%GOLD$4,075.60+3.43%OIL$88.71-7.68%
Smart Investors Daily
SID Premium
GL

NASDAQ · GLUE

Monte Rosa Therapeutics, Inc.

Healthcare · Biotechnology

$10.41

Up+$0.20 (+1.92%)

Updated Nov 4, 2026, 6:28 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.08B
P/E ratio
56.25
Dividend yield
0.00%
52-week range
$9.68 – $25.77
Volume
1.37M
Avg. volume
1.57M

Price performance · GLUE

GLUE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

GLUE closed at $10.41 after 21 trading sessions, up 5.47% for the selected period.

Last close
$10.41
Period change
+5.47%
Period low
$9.74
Period high
$11.36
Daily close
View OHLC price history
GLUE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$10.85$11.005$10.37$10.411.37M
Nov 2, 2026$10.79$11.015$10.43$10.631.77M
Oct 30, 2026$10.85$11.13$10.45$10.761.35M
Oct 29, 2026$11.00$11.20$10.73$10.871.31M
Oct 28, 2026$10.51$10.88$10.40$10.851.63M
Oct 27, 2026$10.47$10.71$10.34$10.661.46M
Oct 26, 2026$10.94$10.94$10.325$10.481.23M
Oct 23, 2026$11.03$11.03$10.61$10.84817.83K
Oct 22, 2026$11.14$11.39$11.00$11.111.28M
Oct 21, 2026$11.38$11.74$11.085$11.221.08M
Oct 20, 2026$10.72$11.42$10.56$11.361.87M
Oct 19, 2026$9.84$10.71$9.76$10.661.93M
Oct 16, 2026$10.18$10.23$9.705$9.74885.43K
Oct 15, 2026$9.95$10.24$9.88$10.121.54M
Oct 14, 2026$9.76$10.105$9.71$9.841.09M
Oct 13, 2026$10.45$10.54$9.8525$9.892.72M
Oct 12, 2026$10.29$10.63$10.14$10.522.09M
Oct 9, 2026$10.36$10.52$10.21$10.301.2M
Oct 8, 2026$10.04$10.38$9.82$10.321.89M
Oct 7, 2026$9.84$10.75$9.68$10.172.08M
Oct 6, 2026$10.38$10.38$9.78$9.871.05M

Latest GLUE news

The latest Smart Investors Daily articles mentioning GLUE.

Stock researchCompany · Overview

GLUE research

Overview

Company profile and research snapshot.

Company profile

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GLUE recent ratings
DateFirmRatingTarget
Oct 5, 2026HC Wainwright & Co.Buy—
Oct 1, 2026HC Wainwright & Co.Buy—
Sep 9, 2026WedbushOutperform—
Aug 25, 2026GuggenheimBuy—
Aug 7, 2026GuggenheimBuy—
Open full forecast

News briefing

Generated Nov 4, 2026, 5:07 PM

Why Is GLUE Down Today?

Monte Rosa Therapeutics (GLUE) is down marginally by $0.05 (0.43%) today, despite a series of positive corporate developments and noteworthy analyst sentiment. The mild decline appears disconnected from the company's recent announcements, suggesting the market may be digesting multiple developments simultaneously or experiencing broader sector headwinds.

    Bottom line: GLUE's modest decline today contrasts sharply with bullish analyst sentiment suggesting >150% upside potential, indicating the market may be undervaluing the company or awaiting concrete clinical progress. Investors should monitor upcoming investor conference presentations and any clinical developments closely, as these could serve as meaningful catalysts for a re-rating if results are positive.

    Yahoo · Nov 3, 2026

    Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 33,775 shares of Monte Rosa Therapeutics common stock,

    Yahoo · Nov 2, 2026

    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

    BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston, MA) – fireside chat, November 9, 2026, at 8:00 a.m. ETUBS Global Biopharma Conference 2026 (London, UK) – fireside chat, November 16, 2026, at 12:00 p.m. G

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By